Skip to main content
Hansa Biopharma AB (publ) (STO:HNSA)
Sweden flag Sweden · Delayed Price · Currency is SEK
29.34
-0.36 (-1.21%)
At close: Mar 9, 2026

Hansa Biopharma AB Revenue

In the year 2025, Hansa Biopharma AB had annual revenue of 222.27M SEK with 29.74% growth. Hansa Biopharma AB had revenue of 75.99M in the quarter ending December 31, 2025, with 134.99% growth.

Revenue
222.27M
Revenue Growth
+29.74%
P/S Ratio
13.43
Revenue / Employee
1.78M
Employees
125
Market Cap
2.99B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025222.27M50.95M29.74%
Dec 31, 2024171.32M37.22M27.76%
Dec 31, 2023134.09M-20.43M-13.22%
Dec 31, 2022154.53M120.65M356.12%
Dec 31, 202133.88M27.78M455.56%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Flerie AB 2.80M
Vicore Pharma Holding AB 3.82M
Egetis Therapeutics AB 62.40M
Diamyd Medical AB 349.00K
Saniona AB 434.40M
BioInvent International AB 226.50M
Genovis AB (publ.) 129.65M
Cantargia AB 316.70M
Revenue Rankings

Hansa Biopharma AB News

More News